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a  b  s  t  r  a  c  t
The  kinetics  of the  humoral  immune  response  was  evaluated  using  the  recombinant  SAG2A protein  com-
paratively  to  soluble  Toxoplasma  antigen  (STAg)  by  ELISA  in  sequential  serum  samples  of patients  with
toxoplasmosis  up to 12  months  of  illness  onset.  The  follow  up of  IgM  and  IgA  levels  to  STAg showed  a
gradual  decrease,  with  the  majority  of  patients  (88%)  seropositive  for  IgM  up to  12 months  of  infection,
whereas  IgA  seropositivity  was  relatively  low  (78%)  compared  to IgM  (100%)  in  the ﬁrst  3 months  of
infection.  The  follow  up of  IgG and IgG1  antibodies  showed  a similar  increasing  proﬁle  for  both  SAG2A
and  STAg,  with  slightly  higher  seropositivity  for STAg.  The  kinetics  of  IgG3  to STAg  was  similar  to  that
of  IgG1,  contrasting  with  the  kinetics  of  IgG3  to SAG2A  that  showed  high  levels  up  to  6 months  of  infec-
tion,  with  continuous  decreasing  over  the time.  Higher  IgG3  seropositivity  to  SAG2A  than  STAg  was  also
observed  in  the  initial  phases  of infection.  A higher  IgG3/IgG1  ratio  for  SAG2A  than  STAg  was  detected
in  the ﬁrst  3 months  of  infection,  with  decreasing  proﬁle  over  the  time.  The  associations  of  IgG3/IgG1
ratio  >  1.0  with  positive  IgM or  IgA  antibodies  were  predominantly  found  in the ﬁrst  3  months  of  infection,
whereas  associations  of IgG3/IgG1  ratio  <  1.0  with  positive  IgM or negative  IgA  antibodies  were  mostly
observed  from  3 to 12  months  of  infection.  In conclusion,  our  results  demonstrate  a  differential  kinetics
of IgG3  antibodies  to  SAG2A  and  STAg  in  patients  with  toxoplasmosis  up  to  12 months  of infection.  Also,
the  IgG3/IgG1  ratio  to SAG2A  in  association  with  classical  serological  markers  of acute  phase  could  be
potential  tools  to distinguish  early  acute  from  convalescent  phases  of  Toxoplasma  gondii  infection.
 . Introduction
Toxoplasma gondii is an obligate intracellular protozoan para-
ite that infects a large number of hosts, including humans [1].  The
cute phase of the infection is generally asymptomatic or with mild
ymptoms in immunocompetent hosts, and the parasite persists
n the chronic phase [2,3]. Severe disease may  occur in immuno-
ompromised individuals and pregnant women that acquire the
rimary infection during gestation, where the passage of the par-
site via placenta to the fetus may  cause abortion, neonatal death
r postnatal complications [4–7].
Toxoplasmosis is routinely diagnosed by the detection of spe-
iﬁc antibodies to T. gondii.  The detection of low titers of IgG
ntibodies with presence of IgM and IgA antibodies is suggestive
f acute phase, while the absence of IgM and IgA antibodies and
resence of high titers of IgG antibodies suggest chronic phase [8].
∗ Corresponding author. Tel.: +55 34 3218 2195; fax: +55 34 3218 2333.
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Unfortunately, the differentiation from acute and chronic phase is
not easy to achieve. In some cases, the IgM antibody can persist
more than one year after the initial infection, whereas the detection
of IgA antibodies to T. gondii is not an accurate marker for diagnosis
[9,10].  The detection of IgG antibodies indicates T. gondii infection,
but it is difﬁcult to estimate the time of infection. At present, the
avidity of IgG antibodies represents a useful tool to differentiate
phases of infection, although the detection of IgG avidity can be
hampered, in some cases, since that the low-avidity IgG antibodies
can be persistent for months, thus not estimating precisely the time
of infection [11].
Sensitivity and speciﬁcity are essential parameters in diagnos-
tic methods for toxoplasmosis to avoid positive- and negative-false
results that could difﬁcult the diagnosis. In most cases, these
parameters are dependent of the antigen utilized in each assay.
In general, the serological kits utilize Toxoplasma lysate antigens
Open access under the Elsevier OA license.obtained from tachyzoites cultured in cell cultures or mouse peri-
toneal exsudates, resulting in differences related to source of
antigens causing considerable variation on the performance of
diagnostic tests [12]. On the other hand, recombinant T. gondii
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roteins have contributed for a reduction in the costs of produc-
ion and puriﬁcation of antigens for diagnostic tests, allowing the
election of speciﬁc antigens for each phase of infection. Thus, the
ssays based on recombinant antigens could be useful to estab-
ish the relative value of each isolated antigen in the determination
f different phases of infection. This information is particularly
mportant for the diagnosis of primary infection during pregnancy,
ainly in cases of risk for transmission of the parasite to the
etus.
A number of studies have reported the potential use of vari-
us recombinant proteins in serological tests for the diagnosis of T.
ondii infection, such as GRA1 (p24), GRA2 (p28), SAG1 (p30), SAG2
p22), ROP1 (p66), ROP2 (p54) and MAG1 (p65, p68) [10,13–16].
mong them, the members of the SAG1 and SAG2 family are par-
icularly attractive since the surface of T. gondii is mostly coated
y these glycosylphosphatidylinositol-anchored antigens [10]. The
rotein SAG2A (22 kDa) is a surface antigen of T. gondii,  expressed
n tachyzoites of the parasite. It is known that SAG2A is important
or the initial attachment and invasion of the parasite to cell hosts,
s well as in the modulation of immune responses [17]. SAG2A is
n immunodominant protein that elicits strong humoral response
nd our previous study showed that IgG and mostly IgG1 antibod-
es from patients with acute phase of toxoplasmosis reacted more
trongly with SAG2A antigens than sera from patients with chronic
hase, suggesting its potential use to characterize the acute phase
f infection [15]. However, it has been little investigated the role of
ther IgG subclasses in the differential diagnosis of the phases of
oxoplasmosis [6].
In the present study, we evaluated the kinetics of the
umoral immune response to the recombinant SAG2A antigen
n comparison with T. gondii soluble antigen (STAg) through
he detection of speciﬁc IgG, IgG1 and IgG3 antibodies in
erum samples of patients with toxoplasmosis in different time
oints of infection. Also, we veriﬁed the association of these
erological markers based on SAG2A reactivity as potential
ools to distinguish early acute from convalescent phase of
oxoplasmosis.
. Materials and methods
.1. Patients and serum samples
This is a prospective longitudinal study that evaluated a total
f 130 serum samples obtained from 19 patients with toxoplas-
osis after different time points of illness onset. The patients
nrolled in the study were attended at the Infectious Disease Cen-
er of the Federal University of Espirito Santo, Vitoria, ES, Brazil,
fter an initial screening by physicians of private clinics or pub-
ic hospitals of the region that directed the patients that ﬁlled the
ollowing criteria of inclusion: male and female patients, age rang-
ng from 7 to 80 years, presence of at least two from the clinical
ignals compatible with the acute phase of toxoplasmosis (weak-
ess, fever, enlarged cervical lymph nodes, headache, arthralgia),
nd with serological evidence of infection characterized by the
resence of IgM and/or IgG antibodies to T. gondii in conventional
erological assays using a commercial kit (ELFA, VIDAS® Toxo IgM
nd IgG II, Biomérieux SA, Lyon, France). Exclusion criteria were
regnancy and/or human immunodeﬁciency virus (HIV)-positive
atients. An average of seven blood samples were collected from
ach patient by venopuncture over the time for 12 months, and
era were stored at −20 ◦C in aliquots until serological assays. The
tudy was approved by the Ethics Committee of the Institution and
nformed consent was obtained from all patients prior to study
ntry.etters 143 (2012) 193– 201
2.2. Production of soluble Toxoplasma antigen (STAg) and
recombinant SAG2A antigen
Tachyzoites of the RH strain were maintained by serial pas-
sage in Swiss mice for 48–72 h [18]. The peritoneal exudates
from infected mice were harvested and washed in phosphate-
buffered saline (PBS, pH 7.2). Parasite suspensions were adjusted
to 1 × 108 tachyzoites/mL and submitted to freeze–thawing and
sonication cycles in the presence of protease inhibitors [19]. The
preparation was centrifuged at 10,000 × g for 15 min  at 4 ◦C; the
supernatants were collected, the protein content was  determined
by the method of Bradford [20] and aliquots were stored at −20 ◦C
until used as T. gondii soluble antigen (STAg).
Recombinant SAG2A production was  prepared as previously
described [15]. Brieﬂy, DNA from T. gondii RH strain tachy-
zoites were used as the template for ampliﬁcation of the SAG2A
gene by a standard polymerase chain reaction (PCR) protocol,
using the following primers containing NdeI and HindIII recog-
nition sequences: 5′-CAAGTTCGCTCATATGTCCACCACCG-3′ and
5′-ACTTTCGCAAAGCTTCTCCGAAAG-3′. The PCR product (607 bp)
was digested and inserted in NdeI/HindIII sites of the pET28a
vector. The resulting vector containing the sequence encoding
SAG2A molecule in fusion with his-tag sequence (pET28a-SAG2A)
was transformed in BL21 (DE) Escherichia coli. The transformed
BL21 (DE) bacteria were grown in LB media supplemented with
50 g/mL of kanamycin at 37 ◦C up to reach an optical density (OD)
at 600 nm of 0.5. For SAG2A protein expression, the culture was
induced with 0.5 mM isopropyl--d-thiogalactopyranoside (IPTG;
Sigma Chemical Co., St Louis, USA), with slow shaking (90 rpm) at
20 ◦C for 16 h. Cells were harvested by centrifugation, the pellet
was resuspended in lysis buffer (50 mM Tris–HCl, pH 8.0, 200 mM
sucrose, 0.2% Triton X-100 and 1 mM PMSF), and disrupted with
freeze-and-thaw (six cycles) and sonication (ten 20-s cycles at
90% of power). Insoluble debris was removed by centrifugation
at 10,000 × g for 20 min  at 4 ◦C and the supernatant was loaded
into a NTA-Ni column (Qiagen) previously equilibrated in 50 mM
phosphate buffer, pH 8.0. The unbound proteins were removed
by washing buffer (50 mM NaH2PO4 and 300 mM NaCl, pH 8.0).
The SAG2A protein was eluted from the column with the same
equilibrium buffer supplemented with 250 mM  imidazole. SAG2A
fractions were pooled and dialyzed against PBS, the protein concen-
tration was determined by the method of Bradford [20] and aliquots
were stored at −20 ◦C.
2.3. Capture ELISA for detection of IgM and IgA antibodies to T.
gondii
Capture ELISA for IgM and IgA antibodies to T. gondii were
performed in house as previously described [21]. Brieﬂy, high-
binding microtiter plates (Costar-Corning Incorporated, New York,
USA) were coated overnight at 4 ◦C with goat anti-human IgM or
anti-human IgA antibodies (10 g/mL) (Sigma) diluted in 0.06 M
carbonate buffer (pH 9.6). Plates were washed three times with PBS
plus 0.05% Tween 20 (PBS-T) and blocked with PBS-T supplemented
with 5% skim fat milk for 1 h at room temperature. Subsequently,
wells were incubated with serum samples, in duplicate, diluted at
1:16 for 2 h at 37 ◦C and then with STAg (100 g/mL) for 2 h at 37 ◦C.
The bound antigen was  detected with a peroxidase-labeled rabbit
F(ab′)2 anti-T. gondii conjugate (prepared as previously described
[22]) diluted 1:50 and incubated for 1 h at 37 ◦C. The assay was
developed by adding the enzyme substrate (0.03% H2O2 and 2,2′-
azino-bis-3-ethyl-benzothiazoline sulfonic acid [ABTS, Sigma] in
0.07 M citrate phosphate buffer, pH 4.2). The optical density (OD)
was read at 405 nm in a plate reader (Titertek Multiskan Plus spec-
trophotometer, Flow Laboratories, McLean, USA). The cutoff of the
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Fig. 1. Kinetics of IgM and IgA antibodies to Toxoplasma gondii determined by
capture ELISA using soluble tachyzoite antigen (STAg) in sera from patients with
toxoplasmosis at different time points of illness onset. Data represent the mean and
SEM of ELISA index (EI) values obtained from serum samples from 19 patients that
were grouped within each time (0–3, 3–6, 6–9, and 9–12 months) of infection. Dif-
ferent letters (a–c) indicate statistically signiﬁcant differences between each time ofS.S. Santana et al. / Immuno
eaction was calculated as the mean OD of negative control sera
lus 3 standard deviations. Antibody titers were expressed as ELISA
ndex (EI), according to the following formula: EI = OD sample/OD
utoff, as described elsewhere [23]. Samples with EI values ≥ 1.2
ere considered positive.
All serum samples were also analyzed for IgM anti-T. gondii by
sing a commercial kit (ELFA, VIDAS® Toxo IgM, Biomérieux SA)
fter different time points of illness onset, following the manufac-
urer’s instructions.
.4. Indirect ELISAs for detection of IgG and subclasses (IgG1 and
gG3) to SAG2A and STAg
Indirect ELISAs for the detection of IgG antibodies and their sub-
lasses (IgG1, IgG2, IgG3, and IgG4) to SAG2A and STAg were also
erformed in house. Brieﬂy, high-binding microtiter plates (Costar-
orning Incorporated) were coated with 5 g/mL of SAG2A or STAg
iluted in 0.06 M carbonate buffer (pH 9.6) overnight at 4 ◦C. Plates
ere washed with PBS-T and blocked with PBS-T supplemented
ith 5% skim fat milk for 1 h at room temperature. Subsequently,
ells were incubated with serum samples, in duplicate, diluted at
:64 for 2 h at 37 ◦C. Plates were washed six times and incubated
ith peroxidase-labeled goat anti-human IgG (1:1000, Sigma) for
 h at 37 ◦C. Plates were washed again and the enzymatic activ-
ty was revealed by adding the enzyme substrate (0.03% H2O2 and
.01 M ABTS). The OD values were determined at 405 nm.  Results
ere expressed as ELISA index (EI) as described for capture ELISA
or IgM and IgA antibodies.
All serum samples were also analyzed for IgG anti-T. gondii by
sing a commercial kit (ELFA, VIDAS® Toxo IgG II, Biomérieux SA)
fter different time points of illness onset, following the manufac-
urer’s instructions.
For the detection of IgG subclasses, microtiter plates were
oated as described above, washed with PBS-T and blocked with
BS-T plus 1% bovine serum albumin (PBS-T–BSA) for 1 h at room
emperature. Subsequently, wells were incubated with serum sam-
les diluted at 1:64 in PBS-T–BSA for 2 h at 37 ◦C. The wells were
ashed six times and incubated with the respective biotinylated
econdary antibodies (Sigma) as follows: goat anti-human IgG1
1:1000), anti-human IgG2 (1:1000), anti-human IgG3 (1:1000), or
nti-human IgG4 (1:1000) for 1 h at 37 ◦C. Plates were washed again
nd incubated with streptavidin–peroxidase (1:1000, Sigma) for
0 min  at room temperature. Plates were washed and the reaction
as revealed as described above.
.5. Statistical analyses
Statistical analyses were performed using the GraphPad Prism
. 5.0 (GraphPad Software, San Diego, USA). Antibody levels were
ompared between the antigens in different time points using
aired or unpaired Student’s t test, when appropriated. Association
etween IgG3/IgG1 ratio with IgA or IgM antibodies and positiv-
ty for both antigens were analyzed by the Fisher exact test or
hi-square test. The sensitivity and speciﬁcity of assay combina-
ions were evaluated by serial tests using the multiple diagnostic
ests from the Win  Episcope 2.0 software (www.clive.ed.ac.uk). For
his purpose, the sensitivity was deﬁned as the percentage of posi-
ive results in samples from 0 to 3 months of infection (early acute
hase) and the speciﬁcity as the percentage of negative results in
amples from 3 to 12 months of infection (convalescent phase).
he positive and negative predictive values were not possible to
e calculated in the present study due to prevalence uncertainty as
reviously described [24]. P values <0.05 were considered statisti-
ally signiﬁcant.infection determined by repeated measures ANOVA and Bonferroni multiple com-
parison post-test (P < 0.05). Percentage of positive IgM and IgA samples are also
indicated in each time of infection.
3. Results
3.1. Kinetics of IgM and IgA antibodies to STAg
The kinetics of the humoral immune response to T. gondii in
patients with acute toxoplasmosis was initially evaluated by mea-
suring IgM and IgA antibodies to STAg by capture ELISA in different
time points. The highest IgM level was found in the early acute
phase (0–3 months) of infection, with signiﬁcant decrease at 3–6
and 6–9 months of illness onset (P < 0.05) (Fig. 1). Mean IgM levels
were similar from 6 to 12 months of infection, with 100% of posi-
tive samples up to 9 months and even maintaining 88% of positivity
from 9 to 12 months of illness onset (Fig. 1). These ﬁndings were
conﬁrmed when using a commercial test (ELFA, VIDAS® Toxo IgM),
that provided 100% positive IgM samples up to 6 months of infec-
tion, 92% from 6 to 9 months, and 83% from 9 to 12 months of illness
onset (data not shown).
A gradual reduction in IgA levels to STAg was  also observed
during the months analyzed, although with lower mean levels
as compared to IgM (Fig. 1). IgA levels were higher in the initial
phases (0–6 months) of infection than the subsequent time points
(P < 0.05). Mean IgA levels maintained above the cutoff value during
the follow-up, but only 78% of positive IgA samples were detected
in the ﬁrst 3 months of infection, with gradual decrease for 53%, 52%
and 38% in the 2nd, 3rd, and 4th time points analyzed, respectively.
3.2. Kinetics of IgG and subclasses (IgG1 and IgG3) antibodies to
SAG2A and STAg
In order to analyze the kinetics of IgG and subclasses, an indi-
rect ELISA was carried out using recombinant SAG2A in comparison
with STAg (Fig. 2). The comparative analysis between IgG antibod-
ies to SAG2A and STAg displayed a similar reactivity proﬁle that was
increasing up to 6–9 months of infection, although a higher reactiv-
ity was  observed to SAG2A than STAg in each time point analyzed
(P < 0.001) (Fig. 2A). The kinetics of IgG1 antibodies to SAG2A and
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Fig. 2. Kinetics of IgG (A), IgG1 (B) and IgG3 (C) antibody isotypes to Toxoplasma gondii determined by indirect ELISA using soluble tachyzoite antigen (STAg) or recombinant
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ean and SEM of ELISA index (EI) values obtained from serum samples from 19 pat
igniﬁcant differences between STAg and SAG2A were determined by the paired St
TAg showed an increase in the reactivity from 0 to 6 months of
nfection, with a slight decrease or maintenance of their levels up
o 12 months of illness onset, but with no signiﬁcant difference
etween the antigens in each time point (Fig. 2B).
The response proﬁle of IgG3 antibodies to SAG2A showed high
evels in the initial phases (0–6 months) of infection, followed by
 continuous decrease over the time (Fig. 2C). In contrast, when
LISA was developed with STAg as antigen, IgG3 levels were low in
he ﬁrst 3 months of infection, followed by a slight increase at 3–6
onths and reduction in the subsequent time points. Interestingly,
gG3 levels to SAG2A were signiﬁcantly higher than to STAg in the
rst 3 months of infection (P < 0.0001).
To underline the differential proﬁle of the IgG3 response to
AG2A and STAg, the ratio between the levels of IgG3 and IgG1
ntibodies was also analyzed over the time (Fig. 2D). The IgG3/IgG1
atio to SAG2A was higher than 1.0 in the ﬁrst 3 months of infec-
ion and showed a marked decrease during the follow-up, while the
gG3/IgG1 ratio to STAg was lower than 1.0 and constant over the
ime. Also, the IgG3/IgG1 ratio to SAG2A was signiﬁcantly higher
han to STAg only in the ﬁrst 3 months of infection (P = 0.0009).
erum samples were also analyzed for the detection of IgG2 and
gG4 antibodies in indirect ELISA, but they were non-reactive to
AG2A and STAg (data not shown).
.3. Antibody isotype positivity to STAg and SAG2A
Differences among the percentages of antibody isotype positiv-
ty for SAG2A and STAg in each time point are demonstrated in
ig. 3. Regarding the IgG antibody (Fig. 3A), positivity for STAg was
ncreasing, with 85% in the ﬁrst 3 months, 97.5% at 3–6 months
nd 100% from 6 to 12 months of infection. Similar results were
btained when using a commercial test (ELFA, VIDAS® Toxo IgG II),
ith 88% of positive IgG sera up to 3 months of infection and 100%
rom 3 to 12 months of illness onset (data not shown). IgG positivityss onset. The kinetics of the IgG3/IgG1 ratio is also shown (D). Data represent the
that were grouped within each time (0–3, 3–6, 6–9, and 9–12 months) of infection.
’s t test in each time point. **P < 0.001; ***P < 0.0001.
for SAG2A was  also increasing, ranging from 78% to 92%, but slightly
lower than for STAg, although with no signiﬁcant difference in any
time point analyzed.
The IgG1 positivity for STAg was higher from 3 to 12 months of
infection (>95%) as compared to the ﬁrst 3 months (80%) (P < 0.05).
On the other hand, IgG1 positivity for SAG2A was  lower than for
STAg in all time points (66–85%), even though statistical signiﬁ-
cance was  achieved only at 6–9 months of infection (P < 0.05).
As shown in Fig. 3C, IgG3 positivity for STAg was lower in the
ﬁrst 3 months of infection (58%) as compared to subsequent times
(75–88%), with signiﬁcant difference only at 3–6 months of infec-
tion (P < 0.05). In contrast, IgG3 positivity for SAG2A was  high from
0 to 9 months (>92%), with signiﬁcant decrease at 9–12 months
(67%) of infection. When comparing the antigens in each time point,
IgG3 positivity was signiﬁcantly higher for SAG2A than STAg at 0–3
months and 6–9 months of infection (P < 0.05).
The positive serum samples with high IgG3/IgG1 ratio (>1.0)
were also analyzed during the follow-up (Fig. 3D). It was observed
higher positivity for SAG2A in the ﬁrst 3 months of infection when
compared to the subsequent time points (P < 0.05). The comparative
analysis between SAG2A and STAg showed that the positivity of
IgG3/IgG1 ratio > 1.0 for SAG2A was  higher than STAg in all time
points (P < 0.05). No signiﬁcant difference was  observed for STAg in
any time points analyzed.
3.4. Association between IgG3/IgG1 ratio to SAG2A and classical
serological markers
The association between the serological results based on SAG2A
reactivity (IgG3/IgG1 ratio) and classical serological markers to
characterize acute phase of toxoplasmosis (IgM and IgA antibodies
to STAg) was evaluated in each time point (Figs. 4 and 5). Serolog-
ical results showing a high IgG3/IgG1 ratio (>1.0) and positive IgM
levels (EI ≥ 1.2) were predominantly found in the ﬁrst 3 months of
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s  also shown (D). #Signiﬁcant differences as compared to 0–3 months of infection
P  < 0.05 determined by the Chi-square test).
nfection (74%, Fig. 4A), with signiﬁcant reduction in the subsequent
ime points (50%, 37.5% and 32%; Fig. 4B–D, respectively) (P < 0.05).
n the other hand, the association between a low IgG3/IgG1 ratio
<1.0) and positive IgM levels was mainly noted from 3 to 12 months
50%, 62.5%, and 56%; Fig. 4B–D, respectively) in comparison with
he ﬁrst 3 months of infection (24%, Fig. 4A) (P < 0.05).
As shown in Fig. 5, the association between IgG3/IgG1 ratio > 1.0
nd positive IgA levels (EI ≥ 1.2) was mostly veriﬁed from 0 to 3
onths of infection (58.3%, Fig. 5A), with signiﬁcant decrease in
he subsequent times (25%, 29.7%, and 16%; Fig. 5B–D) (P < 0.05).
n contrast, serological results with low IgG3/IgG1 ratio (<1.0)
nd negative IgA levels (EI < 1.2) were predominantly found from
 to 12 months (37% and 44%; Fig. 5C and D) in compari-
on with 0–6 months of infection (9% and 22%; Fig. 5A and B)
P < 0.05).
.5. Proposed schedule for the diagnosis of toxoplasmosis
From the analysis of our results, we proposed a schedule for
he serodiagnosis of toxoplasmosis in order to complement the
onventional techniques (Fig. 6). Routinely, the serum samples
rom patients with suspect of toxoplasmosis are tested for screen-
ng assays, including the indirect ELISA for IgG and capture ELISA
or IgM and IgA antibodies to T. gondii using STAg as antigen.
erum samples that are nonreagent in these assays are considered–12 months) of infection. Seropositivity of serum samples with IgG3/IgG1 ratio > 1.0
ach antigen. *Signiﬁcant differences between STAg and SAG2A in each time point
negative for T. gondii infection, while those with positivity only for
IgG antibodies are related to chronic phase. The three possible sero-
logical results that could indicate the status of serum samples as
belonging to the acute phase are the concomitant presence of IgG,
IgM, and IgA antibodies, or the presence of IgG and IgM, or the
presence of IgM and IgA, in the absence of IgG antibodies.
In order to better deﬁne this diagnosis status, we proposed as
complementary assays the evaluation of IgG subclasses, especially
IgG1 and IgG3 to SAG2A by indirect ELISA, characterizing two pos-
sible outcomes: early acute and convalescent phases. The early
acute phase, in our study, was established by the association of
high IgG3/IgG1 ratio (>1.0) with positive IgM and/or IgA antibod-
ies. Thus, when using as ﬁrst test the in house capture IgM-ELISA
(100% sensitivity and 3% speciﬁcity) or capture IgA-ELISA (78%
sensitivity and 52% speciﬁcity) and as second test the IgG3/IgG1
ratio assay (76% sensitivity and 56% speciﬁcity), the combination
of these serial tests resulted in signiﬁcant increase of speciﬁcity
for IgG3/IgG1 ratio (>1.0) with positive IgM (58%) or IgA (79%) to
include a sample within 0–3 months of infection. On the other hand,
the convalescent phase was  characterized by low IgG3/IgG1 ratio
(<1.0) associated with the positive IgM and/or negative IgA to T.
gondii. The performance of assay combinations evaluated by serial
tests showed a signiﬁcant increase of speciﬁcity, especially regard-
ing the IgG3/IgG1 ratio (<1.0) and negative IgA (83%) to include a
sample within 6–12 months of infection.
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. Discussion
Several reports have demonstrated the use of T. gondii recom-
inant proteins as potential source of antigens for serodiagnosis of
oxoplasmosis instead of conventional extracts of T. gondii tachy-
oites [10,11,14,16,25–28]. The recombinant antigens have been
sed in the development of new tests capable to discriminate acute
rom chronic phase of T. gondii infection [29,30]. Considering the
otential damages in fetus associated with congenital toxoplas-
osis, the development of new serologic tests that are able to
iscriminate recent from past infections, including the early acute
hase and convalescent phase, will be clinically relevant, especially
uring pregnancy [10].
Potential markers for acute phase of toxoplasmosis were already
escribed using the recombinant MAG1 [16] and GRA2 antigens
14,31]. Recently, our previous study reported the use of recombi-
ant SAG2A in ELISA, demonstrating increased positivity for SAG2A
n acute phase sera, and indicating that SAG2A could be a potential
iagnostic marker for distinguishing the infection phases [15]. In
he present study, we evaluated the kinetics of antibodies against
. gondii in sequential serum samples from patients with toxoplas-
osis, utilizing the recombinant SAG2A in comparison with STAg.
First, we characterized the proﬁle of IgM and IgA to STAg in
erum samples grouped in four different time points. IgM levels
ere high in the initial phases, decreased over the time, but main-
ained above the cutoff value, with the majority of patients beingentional techniques using soluble antigen (STAg) and new complementary assays
sses (IgG1, IgG3). The IgG3/IgG1 ratio is analyzed in association with the results of
considered positive up to 12 months of infection. This result indi-
cates that high levels of IgM antibodies were produced in early stage
of T. gondii infection and the persistence of IgM antibodies conﬁrms
that this isotype, by itself, has not high accuracy as a marker of acute
phase [9,10],  particularly for predicting the time of infection onset
in pregnant women [32].
Regarding the kinetics of IgA antibodies, IgA levels were lower
when compared with those of IgM and showed a gradual decrease
over the time. Also, IgA seropositivity was relatively low (78%) com-
pared to IgM seropositivity (100%) in the ﬁrst 3 months of infection.
IgA antibodies have been considered interesting markers of acute
toxoplasmosis because the kinetics of this isotype is earlier than
of IgM antibodies [33]. However, the main problem in the detec-
tion of IgA isotype at routine laboratory is the low sensitivity of
the assays, since the detection of IgA to T. gondii showed limited
diagnostic value, even using the capture ELISA [34]. Such fact is
particularly important in neonatal screening for congenital toxo-
plasmosis, since previous reports showed a poor performance of IgA
tests in newborn sera, especially when their mothers seroconverted
in early pregnancy [35].
In the present study, the follow up of IgG antibodies showed a
similar kinetics for both antigens, although with higher IgG levels
to SAG2A than STAg. These ﬁndings reinforce our previous reports
that showed higher IgG reactivity to SAG2A than STAg in acute
phase sera [15]. However, IgG seropositivity to both antigens was
similar, with slightly lower positive rate in samples from 0 to 3
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onths of infection, compatible with an early acute phase, whose
ata were conﬁrmed by a commercial test (ELFA, VIDAS® Toxo IgG
I). Previous studies have evaluated the kinetics of IgG antibodies
o T. gondii recombinant proteins, such as ROP2, GRA1 or GRA6 Nt,
n infants with congenital toxoplasmosis [36] or pregnant women
37], showing a highly variable IgG proﬁle. Thus, SAG2-related pro-
eins may  be potential tools in kinetics studies for IgG antibodies
o T. gondii.
Differences in biological properties of human IgG subclasses
ave encouraged the investigation of IgG isotype responses to a
ariety of infectious agents [15,29,38,39].  The sequential determi-
ation of IgG subclasses was evaluated in primary and reactivating
oxoplasmosis, and IgG1 was the predominant isotype at the dif-
erent stages of infection [40]. In our study, the kinetics of IgG1 to
AG2A and STAg was similar in patients with toxoplasmosis up to
2 months of infection, although higher IgG1 reactivity to SAG2A
as observed in sera from acute than chronic phase in our previ-
us report [15]. These divergences can be due to differences in the
tudy designs, particularly related to the time of illness onset, since
he data herein shown represent a longitudinal study, whereas our
revious data were obtained from a prevalence study, with two
ell deﬁned serologically groups [15].
The kinetics of IgG3 to STAg was increasing and similar to that
bserved for IgG1 antibodies, contrasting to the kinetics of IgG3
oward SAG2A, which showed high levels from 0 to 6 months of
nfection, with continuous decreasing over the time. IgG3 seropos-
tivity to SAG2A was higher than to STAg in the initial phases of
nfection. It is noteworthy that IgG3 reactivity to T. gondii protein of
2 kDa (SAG2) was also detected in serum samples from patients in
he acute phase [39]. Interestingly, the active fetal synthesis of the
gG3 isotype has been related to clinical problems, while the IgG1
ynthesis was associated with the protection from damage [6]. Also,
hese isotypes were related with the respective cytokine pheno-
ypes, suggesting nonprotective and protective roles in congenital
oxoplasmosis [6].  For IgG3, an explanation for its nonprotective
ole can be related to high afﬁnity of this isotype for the inhibitory
ignal-linked Fc-R [immunoreceptor tyrosine-based inhibition
otif (ITIM)], which downregulates immune functions [41]. Thus,
AG2A could represent a key parasite molecule to induce early IgG3
ynthesis, contributing to evasion mechanisms of the parasite of the
mmune response.
To reinforce these ﬁndings, IgG3/IgG1 ratios were analyzed and
e observed higher IgG3/IgG1 ratio to SAG2A than STAg in the ﬁrst
 months of infection. In addition, a high percentage of serum sam-
les with IgG3/IgG1 ratio > 1.0 to SAG2A than STAg was  detected in
ll time points, particularly from 0 to 3 months of infection. These
ndings reinforce the usefulness of this parameter as an additional
ool to be considered together with other serological markers to
stablish the diagnosis status for toxoplasmosis. Thus, the associa-
ion between high IgG3/IgG1 ratio (>1.0) to SAG2A and positive IgM
o STAg was predominantly found in sera from patients from 0 to 3
onths of infection, indicating this combination of tests as useful
ools to increase the speciﬁcity and to better characterize the early
cute phase. On the other hand, the association of low IgG3/IgG1
atio (<1.0) with positive IgM was predominantly detected from
 to 12 months of infection, thus excluding the ﬁrst 3 months of
nfection and indicating a convalescent phase of toxoplasmosis.
egarding the IgA isotype, we observed that the association of high
gG3/IgG1 ratio to SAG2A with positive IgA to STAg was  predom-
nantly detected from 0 to 3 months of infection, characterizing
he early acute phase. In contrast, the low IgG3/IgG1 ratio associ-
ted with negative IgA was mostly found from 6 to 12 months of
nfection, suggesting the convalescent phase of toxoplasmosis.
In conclusion, the present study constitutes the ﬁrst effort to
larify the kinetics of IgG antibodies and subclasses against the
ecombinant SAG2A protein from T. gondii in sequential samples
[
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from patients with toxoplasmosis. Our results demonstrate a differ-
ential kinetics of IgG3 antibodies to SAG2A comparatively to STAg
and the association of the IgG3/IgG1 ratio to SAG2A with classical
serological markers of acute phase could be potential tools to dis-
tinguish early acute from convalescent phases of T. gondii infection.
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